CU20120080A7 - Formulaciones de anticuerpo - Google Patents
Formulaciones de anticuerpoInfo
- Publication number
- CU20120080A7 CU20120080A7 CU2012000080A CU20120080A CU20120080A7 CU 20120080 A7 CU20120080 A7 CU 20120080A7 CU 2012000080 A CU2012000080 A CU 2012000080A CU 20120080 A CU20120080 A CU 20120080A CU 20120080 A7 CU20120080 A7 CU 20120080A7
- Authority
- CU
- Cuba
- Prior art keywords
- antibody formulations
- formulations
- cryoprotectants
- cryoprotectant
- buffer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002577 cryoprotective agent Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2859CH2009 | 2009-11-20 | ||
| PCT/IB2010/055296 WO2011061712A1 (en) | 2009-11-20 | 2010-11-19 | Formulations of antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20120080A7 true CU20120080A7 (es) | 2012-10-15 |
Family
ID=44059267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2012000080A CU20120080A7 (es) | 2009-11-20 | 2012-05-21 | Formulaciones de anticuerpo |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20120231009A1 (en, 2012) |
| EP (2) | EP3721904B1 (en, 2012) |
| JP (2) | JP5896471B2 (en, 2012) |
| KR (1) | KR101333276B1 (en, 2012) |
| CN (1) | CN102770157B (en, 2012) |
| AU (1) | AU2010320515B2 (en, 2012) |
| BR (1) | BR112012012080B1 (en, 2012) |
| CA (1) | CA2781467C (en, 2012) |
| CU (1) | CU20120080A7 (en, 2012) |
| DK (1) | DK3721904T3 (en, 2012) |
| ES (1) | ES2897500T3 (en, 2012) |
| IL (1) | IL219884A (en, 2012) |
| MX (1) | MX2012005863A (en, 2012) |
| MY (1) | MY165614A (en, 2012) |
| NZ (1) | NZ600096A (en, 2012) |
| PL (1) | PL3721904T3 (en, 2012) |
| PT (1) | PT3721904T (en, 2012) |
| RU (1) | RU2548772C2 (en, 2012) |
| WO (1) | WO2011061712A1 (en, 2012) |
| ZA (1) | ZA201204459B (en, 2012) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| DK2993186T3 (da) | 2008-03-14 | 2019-11-25 | Biocon Ltd | En monoklonal antistof og en fremgangsmåde hertil |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| AR084937A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos frente a pcsk9 para uso en metodos de tratamiento basados en regimenes de dosificacion particulares |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| CN103930444B (zh) | 2011-09-16 | 2020-08-04 | 瑞泽恩制药公司 | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 |
| WO2013112438A1 (en) | 2012-01-23 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| EA029215B1 (ru) | 2012-09-07 | 2018-02-28 | Кохерус Байосайенсис, Инк. | Стабильные водные составы адалимумаба |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| LT2916866T (lt) | 2012-11-06 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Bispecifinių t ląstelių aktyvatorių (bites) kompozicija |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014294616B2 (en) | 2013-07-23 | 2019-07-11 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| MX2016006226A (es) | 2013-11-12 | 2016-09-07 | Sanofi Biotechnology | Regimenes de dosificacion para uso con inhibidores de pcsk9. |
| US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
| RU2735521C2 (ru) | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN104922668B (zh) * | 2014-12-10 | 2019-08-23 | 信达生物制药(苏州)有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| WO2018060210A1 (en) * | 2016-09-27 | 2018-04-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| WO2018073734A1 (en) | 2016-10-21 | 2018-04-26 | Biocon Limited | A monoclonal antibody and a method of use for the treatment of lupus |
| CN106800598B (zh) * | 2017-02-09 | 2020-08-07 | 广州桂雨生物科技有限公司 | 一种抗体保存液及其制备方法 |
| MX2020009935A (es) * | 2018-03-23 | 2021-01-08 | Abbvie Deutschland | Formulaciones acuosas y estables de anticuerpos anti-tau. |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| US11498626B2 (en) | 2020-11-11 | 2022-11-15 | Rivian Ip Holdings, Llc | Vehicle tailgate assembly |
| CN113289027B (zh) * | 2021-05-18 | 2022-07-01 | 中国兽医药品监察所 | 一种通用型单克隆抗体耐热保护剂 |
| EP4605002A1 (en) * | 2022-10-17 | 2025-08-27 | BeiGene Switzerland GmbH | Formulations containing anti-tigit antibody and methods of use thereof |
| CN117214426A (zh) * | 2023-09-20 | 2023-12-12 | 暨南大学 | 一种用于免疫组织化学检测的抗体稀释液及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| DK2275119T3 (da) * | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US5810597A (en) * | 1996-06-21 | 1998-09-22 | Robert H. Allen, Jr. | Touch activated audio sign |
| AU2001277781A1 (en) | 2000-08-11 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| BRPI0403964B8 (pt) * | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| EP3037544A1 (en) * | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases |
| AU2007260769A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Llc | Lyophilized formulations of anti-EGFR antibodies |
| MX2009006199A (es) * | 2006-12-11 | 2009-06-22 | Hoffmann La Roche | Formulacion parenteral de anticuerpos abeta. |
| CN101199483B (zh) * | 2006-12-14 | 2011-01-26 | 上海中信国健药业股份有限公司 | 一种稳定的抗her2人源化抗体制剂 |
| WO2008077356A1 (es) * | 2006-12-26 | 2008-07-03 | Centro De Inmunolgía Molecular | Composiciones farmacéuticas con capacidad de inducción de apoptosis en células tumorales, útiles para el diagnóstico y tratamiento de la leucemia linfocítica crónica b. |
| PE20081610A1 (es) * | 2007-01-09 | 2008-12-09 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| JP5513380B2 (ja) * | 2007-06-25 | 2014-06-04 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合剤の組成物 |
| WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
-
2010
- 2010-11-19 CA CA2781467A patent/CA2781467C/en active Active
- 2010-11-19 NZ NZ600096A patent/NZ600096A/xx unknown
- 2010-11-19 MX MX2012005863A patent/MX2012005863A/es active IP Right Grant
- 2010-11-19 RU RU2012125254/15A patent/RU2548772C2/ru active
- 2010-11-19 AU AU2010320515A patent/AU2010320515B2/en active Active
- 2010-11-19 EP EP20174783.9A patent/EP3721904B1/en active Active
- 2010-11-19 ES ES20174783T patent/ES2897500T3/es active Active
- 2010-11-19 PL PL20174783T patent/PL3721904T3/pl unknown
- 2010-11-19 BR BR112012012080-8A patent/BR112012012080B1/pt active IP Right Grant
- 2010-11-19 CN CN201080060508.0A patent/CN102770157B/zh active Active
- 2010-11-19 WO PCT/IB2010/055296 patent/WO2011061712A1/en active Application Filing
- 2010-11-19 KR KR1020127015910A patent/KR101333276B1/ko active Active
- 2010-11-19 PT PT201747839T patent/PT3721904T/pt unknown
- 2010-11-19 MY MYPI2012002248A patent/MY165614A/en unknown
- 2010-11-19 US US13/510,929 patent/US20120231009A1/en not_active Abandoned
- 2010-11-19 EP EP10831248.9A patent/EP2501408B1/en active Active
- 2010-11-19 JP JP2012539465A patent/JP5896471B2/ja active Active
- 2010-11-19 DK DK20174783.9T patent/DK3721904T3/da active
-
2012
- 2012-05-20 IL IL219884A patent/IL219884A/en active IP Right Grant
- 2012-05-21 CU CU2012000080A patent/CU20120080A7/es unknown
- 2012-06-18 ZA ZA2012/04459A patent/ZA201204459B/en unknown
-
2015
- 2015-12-28 JP JP2015256586A patent/JP2016104780A/ja active Pending
-
2018
- 2018-11-20 US US16/197,228 patent/US20190321285A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,316 patent/US20210290525A1/en not_active Abandoned
-
2023
- 2023-05-19 US US18/199,675 patent/US20240058263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20120080A7 (es) | Formulaciones de anticuerpo | |
| CL2015001984A1 (es) | (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. | |
| CR11005A (es) | Formulaciones estables de anticuerpos | |
| CY1121420T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| AR079556A1 (es) | Formacion de anticuerpos | |
| CO6751287A2 (es) | Composición antigénetica de micobacteria | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| PH12014501628A1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| PE20141175A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| WO2008008364A3 (en) | Enhanced stability phenylephrine liquid compositions | |
| BRPI0915076A2 (pt) | composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas. | |
| DOP2009000157A (es) | Agentes para combatir parasitos en animales | |
| WO2011103490A3 (en) | INTEGRIN αVβ8 NEUTRALIZING ANTIBODY | |
| AR061400A1 (es) | Agentes para suprimir el dano a los islotes transplantados despues del transplante de islotes | |
| AR061348A1 (es) | Preparados estables de laquinimod | |
| CL2012002695A1 (es) | Articulo para fumar, que comprende una primera parte que contiene una fuente de material para fumar y una segunda parte que tiene al menos un extremo que esta configurado para desplazarse en relacion con la primera parte, en donde el articulo ademas comprende un agente modificador de humo que se libera en el articulo para fumar; y envase. | |
| CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
| CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
| EP2507381A4 (en) | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS | |
| UY29701A1 (es) | Formulaciones líquidas para la administración controlada de derivados de bencisoxazol | |
| ECSP10010588A (es) | Formulacion de medicamento solida con liberacion retardada | |
| CL2013000098A1 (es) | Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. | |
| AR053541A1 (es) | Combinacion de xolair con agente inmunosupresor | |
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE | |
| WO2011028961A3 (en) | Anti-botulism antibody coformulations |